Timpani Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Timpani Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-14,982	Closed	-$1.18M	–	118
2017 Q2	$1.18M	Buy	+14,982	New	+$1.23M	0.44%	83
2016 Q1	–	Sell	-26,844	Closed	-$2.38M	–	109
2015 Q4	$2.38M	Sell	26,844 -246	-0.9%	-$19.4K	0.97%	48
2015 Q3	$2M	Sell	27,090 -22,364	-45%	-$1.86M	0.81%	60
2015 Q2	$4M	Buy	+49,454	New	+$3.22M	1.16%	37

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Timpani Capital Management's EGRX Position: Q3 2017 in Review

Timpani Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2017, closing a stake of 14,982 shares — an estimated $1.18M sold.

Timpani Capital Management first reported a position in EGRX in Q2 2015 and held it in 4 quarters. The position peaked at $4M in Q2 2015. 169 funds tracked by Wall St. Rank hold EGRX as of Q3 2017.

Timpani Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Timpani Capital Management sold 14,982 Eagle Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.18M.
Timpani Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 4 quarters.
Timpani Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $4M in Q2 2015.
169 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2017.

Based on Timpani Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.